Diabetic macular edema (DME) is the most common cause of visual dysfunction in patients with diabetes, with an estimated worldwide prevalence of 7.4%.1 In addition to its effects on individual quality of life, DME poses a significant economic burden on health care systems.2 As such, identifying the most efficient methods of treatment and factors associated with therapeutic success are prudent.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rohowetz LJ, Sabates NR, Koulen P. Measuring Anatomical Outcomes of Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema With Artificial Intelligence—A Step Toward Individualized Medicine. JAMA Ophthalmol. Published online July 23, 2020. doi:10.1001/jamaophthalmol.2020.2464
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: